Cargando…
Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objec...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230594/ https://www.ncbi.nlm.nih.gov/pubmed/22162759 http://dx.doi.org/10.1371/journal.pone.0028177 |
_version_ | 1782218075941109760 |
---|---|
author | Lim, Tze-Peng Lee, Winnie Tan, Thean-Yen Sasikala, Suranthran Teo, Jocelyn Hsu, Li-Yang Tan, Thuan-Tong Syahidah, Nur Kwa, Andrea L. |
author_facet | Lim, Tze-Peng Lee, Winnie Tan, Thean-Yen Sasikala, Suranthran Teo, Jocelyn Hsu, Li-Yang Tan, Thuan-Tong Syahidah, Nur Kwa, Andrea L. |
author_sort | Lim, Tze-Peng |
collection | PubMed |
description | OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. METHODS: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ≥3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours. RESULTS: 22 clinical XDR-PA isolates with PB MIC 2–16 µg/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. CONCLUSION: Bactericidal activity with sustained killing effect of ≥99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant. |
format | Online Article Text |
id | pubmed-3230594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32305942011-12-08 Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B Lim, Tze-Peng Lee, Winnie Tan, Thean-Yen Sasikala, Suranthran Teo, Jocelyn Hsu, Li-Yang Tan, Thuan-Tong Syahidah, Nur Kwa, Andrea L. PLoS One Research Article OBJECTIVE: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. METHODS: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ≥3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours. RESULTS: 22 clinical XDR-PA isolates with PB MIC 2–16 µg/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. CONCLUSION: Bactericidal activity with sustained killing effect of ≥99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant. Public Library of Science 2011-12-05 /pmc/articles/PMC3230594/ /pubmed/22162759 http://dx.doi.org/10.1371/journal.pone.0028177 Text en Lim et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Lim, Tze-Peng Lee, Winnie Tan, Thean-Yen Sasikala, Suranthran Teo, Jocelyn Hsu, Li-Yang Tan, Thuan-Tong Syahidah, Nur Kwa, Andrea L. Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title | Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title_full | Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title_fullStr | Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title_full_unstemmed | Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title_short | Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B |
title_sort | effective antibiotics in combination against extreme drug-resistant pseudomonas aeruginosa with decreased susceptibility to polymyxin b |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230594/ https://www.ncbi.nlm.nih.gov/pubmed/22162759 http://dx.doi.org/10.1371/journal.pone.0028177 |
work_keys_str_mv | AT limtzepeng effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT leewinnie effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT tantheanyen effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT sasikalasuranthran effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT teojocelyn effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT hsuliyang effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT tanthuantong effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT syahidahnur effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb AT kwaandreal effectiveantibioticsincombinationagainstextremedrugresistantpseudomonasaeruginosawithdecreasedsusceptibilitytopolymyxinb |